Legend Capital’s Portfolio Company Xbiome Acquires Clinical-Stage Program Targeting Ulcerative Colitis
Legend Capital’s portfolio company Xbiome Inc., an industry-leading and AI-driven microbiome therapeutics company, recently announced that it acquired the clinical-stage
Read More